PEG-Intron™

BIOLOGICAL2 trials

Sponsors

Biolex Therapeutics, Inc., Merck Sharp & Dohme LLC

Conditions

Hepatitis B, ChronicHepatitis C, Chronic

Phase 2

Phase 2B Dose Ranging Study of Locteron Plus Ribavirin to Treat HCV

CompletedNCT00863239

Biolex Therapeutics, Inc.Hepatitis C, Chronic

Start: 2009-03-31End: 2011-11-30Updated: 2012-02-02

Phase 3

A Study of the Safety and Efficacy of Pegylated Inferferon Alfa-2b (PEG-Intron™) Versus Pegylated Interferon Alfa-2a (PEGASYS™) in Participants With Chronic Hepatitis B (P08450)

TerminatedNCT01641926

Merck Sharp & Dohme LLCHepatitis B, Chronic

Start: 2012-11-26End: 2016-01-21Updated: 2018-08-27